Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
A Phase I/II Investigation of Safety and Efficacy of Nivolumab and nab-Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway.
Anticancer Res. 2023 May;43(5):1993-2002. doi: 10.21873/anticanres.16360.
Anticancer Res. 2023.
PMID: 37097693
Clinical Trial.
SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma.
Gordon EM, Chawla SP, Tellez WA, Younesi E, Thomas S, Chua-Alcala VS, Chomoyan H, Valencia C, Brigham DA, Moradkhani A, Quon D, Srikureja A, Wong SG, Tseng W, Federman N.
Gordon EM, et al. Among authors: chua alcala vs.
Cancers (Basel). 2023 Jan 31;15(3):906. doi: 10.3390/cancers15030906.
Cancers (Basel). 2023.
PMID: 36765863
Free PMC article.
Item in Clipboard
Cite
Cite